21:50 , Aug 16, 2019 |  BC Extra  |  Company News

Genentech prices tissue-agnostic therapy at almost half the cost of Bayer's

After scoring FDA approval for its tissue-agnostic therapy Thursday, Genentech Inc. priced Rozlytrek entrectinib Friday at a wholesale acquisition cost of up to $17,050 per month, nearly half that of its only competitor. Rozlytrek is...
22:33 , Aug 15, 2019 |  BC Extra  |  Company News

Genentech gains its first U.S. tissue-agnostic approval with Rozlytrek

Following a Japanese approval in June, Roche’s Genentech unit scored accelerated approval in the U.S. Thursday for its Rozlytrek entrectinib to treat NTRK fusion-positive solid tumors. FDA also approved the inhibitor of ROS1, TrkA, TrkB,...
20:37 , Aug 15, 2019 |  BioCentury  |  Finance

Deciphera’s $400M follow-on adds firepower on strength of GIST readout

Outsized investor demand continues unabated for stocks of companies with late stage clinical success stories, as evidenced by Deciphera’s ability to double the size of its follow-on to $400 million with little to no haircut...
17:59 , Aug 13, 2019 |  BC Extra  |  Clinical News

Big gain for Deciphera as GIST readout portends face-off with Blueprint

New Phase III data in GIST burnished Deciphera's case for an upcoming regulatory submission, pushing the company's market cap to about $1.4 billion while also taking competitor Blueprint Medicines' shares down a few ticks in...
01:02 , Aug 8, 2019 |  BC Extra  |  Company News

Aug. 7 Company Quick Takes: Panel backs narrower PrEP label for Descovy; plus Teva, Blueprint, DBV and more

FDA panel backs narrower PrEP label for Descovy FDA’s Antimicrobial Drugs Advisory Committee voted 16 to 2 that Gilead Sciences Inc. (NASDAQ:GILD) has provided sufficient evidence that Descovy emtricitabine/tenofovir alafenamide is safe and effective for...
23:43 , Aug 2, 2019 |  BC Extra  |  Clinical News

Aug. 2 Clinical Quick Takes: AB Sciences halts metastatic melanoma program; plus NIH, Adaptimmune and more

AB Sciences drops masitinib for melanoma  AB Science S.A. (Euronext:AB) halted development of masitinib for metastatic melanoma despite reporting that the product led to a 33.3% overall response rate (ORR), the primary endpoint in the...
23:33 , Aug 2, 2019 |  BC Extra  |  Company News

Aug. 2 Company Quick Takes: Daiichi's cancer drug gets U.S. approval, plus BioMarin, Acorda, Stemline and more

FDA approves Daiichi's pexidartinib  FDA approved Turalio pexidartinib from Daiichi Sankyo Co. Ltd. (Tokyo:4568) to treat tenosynovial giant cell tumor. A Daiichi spokesperson told BioCentury the drug has been launched at a wholesale acquisition cost...
02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
11:30 , Jul 9, 2019 |  BioCentury  |  Finance

Revolution raises $100M to build out Ras pipeline, explore SHP-2 combos

Following this year’s ASCO fervor around KRAS inhibitors, Revolution Medicines has raised $100 million in a series C round to advance its portfolio of Ras pathway inhibitors, including its own KRAS G12C inhibitor. The financing,...
01:58 , Jun 29, 2019 |  BioCentury  |  Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...